Jun Muto, Hidetoshi Murata, Seiji Shigekawa, Takafumi Mitsuhara, Daisuke Umebayashi, Ryo Kanematsu, Masahiro Joko, Tatsushi Inoue, Tomoo Inoue, Toshiki Endo, Yuichi Hirose, for the Investigators of Intramedullary Spinal Cord Tumors in the Neurospinal Society of Japan
Neurospine 2023;20(3):774-782. Published online September 30, 2023
Objective The characteristics, imaging features, long-term surgical outcomes, and recurrence rates of primary spinal pilocytic astrocytomas (PAs) have not been clarified owing to their rarity and limited reports. Thus, this study aimed to analyze the clinical presentation, radiological features, pathological findings, and long-term outcomes of spinal PAs.
Methods Eighteen patients with spinal PAs who were surgically treated between 2009 and 2020 at 58 institutions were included in this retrospective multicenter study. Patient data, including demographics, radiographic features, treatment modalities, and long-term outcomes, were evaluated.
Results Among the 18 consecutive patients identified, 11 were women and 7 were men; the mean age at presentation was 31 years (3–73 years). Most PAs were located eccentrically, were solid or heterogeneous in appearance (cystic and solid), and had unclear margins. Gross total resection (GTR), subtotal resection (STR), partial resection (PR), and biopsy were performed in 28%, 33%, 33%, and 5% of cases, respectively. During a follow-up period of 65 ± 49 months, 4 patients developed a recurrence; however, the recurrence-free survival did not differ significantly between the GTR and non-GTR (STR, PR, and biopsy) groups.
Conclusion Primary spinal PAs are rare and present as eccentric and intermixed cystic and solid intramedullary cervical tumors. The imaging features of spinal PAs are nonspecific, and a definitive diagnosis requires pathological support. Surgical resection with prevention of neurological deterioration can serve as the first-line treatment; however, the resection rate does not affect recurrence-free survival. Investigation of relevant molecular biomarkers is required to elucidate the regrowth risk and prognostic factors.
Citations
Citations to this article as recorded by
Thoracic intramedullary spinal cord astrocytoma associated with syringomyelia: a case report of gross total resection Igin Ginting, Larona Hydravianto, Lukas Widhiyanto International Journal of Surgery Case Reports.2026; 138(3): 987. CrossRef
The 4S of spinal astrocytoma: specific location, syrinx, spasticity and score on Modified Mccormick Scale (MMS) predict long term outcomes in patients undergoing surgical resection of intramedullary spinal astrocytomas Bhavya Pahwa, Gaurav Singh, Shashank Sharad Kale Journal of Neuro-Oncology.2025; 171(1): 131. CrossRef
Current Treatment Outcomes for Intramedullary Spinal Cord Tumors in Japan Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Akira Ito, Tatsuya Sasaki Japanese Journal of Neurosurgery.2025; 34(6): 327. CrossRef
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors Ines Esparragosa Vazquez, François Ducray Cancers.2024; 16(16): 2781. CrossRef
Cervical Pilocytic Astrocytoma Mimicking Spondylotic Myelopathy: A Case Report and Literature Review Morgane M Soler-Rico, Lina Daoud, Edward Fomekong Cureus.2024;[Epub] CrossRef
The Inside Story of the Multi–center Studies in the Neurospinal Society of Japan Keisuke Takai Spinal Surgery.2024; 38(2): 105. CrossRef
Current Trends and Future Perspective of Intramedullary Spinal Cord Tumor Treatments Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Tatsuya Sasaki Japanese Journal of Neurosurgery.2024; 33(6): 408. CrossRef